Skip to content
Panretin(alitretinoin)
Panretin (alitretinoin) is a small molecule pharmaceutical. Alitretinoin was first approved as Panretin on 1999-02-02. It is used to treat kaposi sarcoma and skin diseases in the USA. It has been approved in Europe to treat kaposi sarcoma. The pharmaceutical is active against vitamin K epoxide reductase complex subunit 1, retinoic acid receptor gamma, retinoic acid receptor beta, and retinoic acid receptor alpha. In addition, it is known to target retinoic acid receptor RXR-alpha, retinoic acid receptor RXR-gamma, and retinoic acid receptor RXR-beta.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
neoplasmsD009369
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Panretin
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Alitretinoin
Tradename
Company
Number
Date
Products
PANRETINConcordia LaboratoriesN-020886 RX1999-02-02
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
panretinNew Drug Application2020-10-09
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
kaposi sarcomaD012514C46
skin diseasesD012871L00-L99
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
D11: Other dermatological preparations in atc
D11A: Other dermatological preparations in atc
D11AH: Agents for dermatitis, excluding corticosteroids
D11AH04: Alitretinoin
L: Antineoplastic and immunomodulating agents
L01: Antineoplastic agents
L01X: Other antineoplastic agents in atc
L01XF: Retinoids for cancer treatment
L01XF02: Alitretinoin
HCPCS
No data
Clinical
Clinical Trials
535 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MelanomaD00854550100722138
Kidney neoplasmsD007680EFO_0003865C64142761142
Renal cell carcinomaD0022928142121
Chronic hepatitis bD019694EFO_0004197B18.111
HivD006678O98.711
Pulmonary tuberculosisD014397EFO_1000049A1511
Liver diseasesD008107EFO_0001421K70-K7711
TransplantationD01418011
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B20172051051
NeoplasmsD009369C803321145
Breast neoplasmsD001943EFO_0003869C5016181130
LeukemiaD007938C9512164128
LymphomaD008223C85.91412223
Myeloid leukemia acuteD015470C92.09162121
NeuroblastomaD009447EFO_0000621119320
Myelodysplastic syndromesD009190D46810217
Skin neoplasmsD012878EFO_0004198C44111113
Non-hodgkin lymphomaD008228C85.948211
Show 24 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ovarian neoplasmsD010051EFO_0003893C56151825
Pancreatic neoplasmsD010190EFO_0003860C25101114
Lung neoplasmsD008175C34.9076112
Non-small-cell lung carcinomaD0022897911
Colorectal neoplasmsD0151796811
Stomach neoplasmsD013274EFO_0003897C16859
SarcomaD012509649
Uterine cervical neoplasmsD002583779
Type 1 diabetes mellitusD003922EFO_0001359E10588
Fallopian tube neoplasmsD005185426
Show 105 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hepatitis cD006526B19.2112
B-cell lymphoma marginal zoneD018442C88.422
Mantle-cell lymphomaD020522C83.122
Bone neoplasmsD001859EFO_0003820D1622
EpendymomaD00480611
AstrocytomaD001254EFO_000027111
OligodendrogliomaD009837EFO_000063111
Primitive neuroectodermal tumorsD01824211
Digestive system neoplasmsD00406711
Myelodysplastic-myeloproliferative diseasesD05443711
Show 15 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Malignant pleural effusionD016066J91.011
Beta-thalassemiaD017086Orphanet_848D56.111
Common variable immunodeficiencyD017074EFO_0000367D8311
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameALITRETINOIN
INNalitretinoin
Description
9-cis-retinoic acid is a retinoic acid in which the exocyclic double bonds have 7E,9Z,11E,13E geometry. It has a role as an antineoplastic agent, a retinoid X receptor agonist, a metabolite and a keratolytic drug. It is a conjugate acid of a 9-cis-retinoate.
Classification
Small molecule
Drug classretinol derivatives
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
Identifiers
PDB3UVV
CAS-ID5300-03-8
RxCUI81864
ChEMBL IDCHEMBL705
ChEBI ID50648
PubChem CID449171
DrugBankDB00523
UNII ID1UA8E65KDZ (ChemIDplus, GSRS)
Target
Agency Approved
VKORC1
VKORC1
RARG
RARG
RARB
RARB
RARA
RARA
Organism
Homo sapiens
Gene name
VKORC1
Gene synonyms
VKOR
NCBI Gene ID
Protein name
vitamin K epoxide reductase complex subunit 1
Protein synonyms
phylloquinone epoxide reductase, vitamin K dependent clotting factors deficiency 2, Vitamin K1 2,3-epoxide reductase subunit 1, vitamin K1 epoxide reductase (warfarin-sensitive)
Uniprot ID
Mouse ortholog
Vkorc1 (27973)
vitamin K epoxide reductase complex subunit 1 (Q9CRC0)
Alternate
RXRA
RXRA
RXRG
RXRG
RXRB
RXRB
Organism
Homo sapiens
Gene name
RXRA
Gene synonyms
NR2B1
NCBI Gene ID
Protein name
retinoic acid receptor RXR-alpha
Protein synonyms
Nuclear receptor subfamily 2 group B member 1, retinoid X nuclear receptor alpha, Retinoid X receptor alpha
Uniprot ID
Mouse ortholog
Rxra (20181)
retinoic acid receptor RXR-alpha (P28700)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 627 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,383 adverse events reported
View more details